Gene therapy using non-viral peptide vector in a canine systemic lupus erythematosus model

Choi, Eung‐Chil; Shin, Ilhoon; Youn, Hwa‐Young; Kim, Dae-Yong; Lee, Hang; Chae, Young-Jin; Lee, Chang-Woo

doi:10.1016/j.vetimm.2004.09.027

Cited by 13 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Construction of the therapeutic CTLA4Ig gene was made as described in our previous report 11. Briefly, the canine CTLA4Ig gene was linked to the human oncostatin M signal sequence for efficient secretion into body fluids and the construct was inserted between the cytomegalovirus promoter for high‐level expression and the poly adenylation sequence of bovine growth hormone (Figure 3A).…”

Section: Methodsmentioning

confidence: 99%

“…Blockade of the B7/CD28 costimulatory interactions with the soluble CTLA4Ig fusion protein has been shown to inhibit humoral immunity 6, graft rejection 7, 8 and graft versus host disease 9, and to ameliorate autoimmune diseases 10 including experimental autoimmune encephalomyelitis, diabetes and collagen‐induced arthritis. In addition, in a previous study, we have shown that gene therapy using the nonviral peptide vector encoding canine CTLA4Ig gene was highly effective in the canine model of systemic lupus erythematosus 11. The strategy of controlling T‐cell activity using CTLA4Ig gene therapy can be applied to other kinds of autoimmune disease.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

The effect of gene therapy using CTLA4Ig/silica‐nanoparticles on canine experimental autoimmune thyroiditis

Choi

Shin

Lee

et al. 2008

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

The effect of gene therapy using CTLA4Ig/silica‐nanoparticles on canine experimental autoimmune thyroiditis

Choi

Shin

Lee

et al. 2008

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…CTLA4Ig treatment elicited improvements in murine SLE, judging from the decrease in proteinuria and increase in survival (Finck et al, 1994). CTLA4Ig gene therapy also had beneficial effects on canine SLE (Choi et al, 2005) and canine experimental autoimmune thyroiditis (Choi et al, 2008). A phase III clinical trial using CTLA4Ig in human SLE is currently underway (Mok, 2010).…”

Section: Therapy Targeting B Cell-t Cell Interaction (Inhibition Of Cmentioning

confidence: 99%

New Therapeutic Challenges in Autoimmune Diseases

Choi¹

2012

Autoimmune Diseases - Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies

View full text Add to dashboard Cite

“…Through further understanding of immunopathogenesis of autoimmune disease and increasing knowledge of the immune system, many researchers are seeking to identify and trial novel immunotherapeutic strategies. These have included recombinant protein or gene therapies aimed at influencing particular immune cells (5) and molecules such as costimulatory molecules (6)(7)(8), cytokines (9) and chemokines (10).…”

Section: Current Therapy and New Prospects For Treatment Of Autoimmunmentioning

confidence: 99%

Adult Stem Cell Therapy for Autoimmune Disease

Choi

2009

Int J Stem Cells

View full text Add to dashboard Cite

Many studies of autologous hematopoietic stem cell transplantation (HSCT) and allogeneic HSCT have been conducted for autoimmune disease in various animal models. Because of the substantial risk of morbidity and mortality associated with allogeneic bone marrow transplantation, autologous transplants justified trying this approach in patient with severe autoimmune disease who were refractory to current treatments. Remission was achieved in some of the patients and some of them relapsed. Recently, many in vitro studies have reported that mesenchymal stem cells (MSC) have immunomodulatory properties and immunosuppressive effects on MHC-mismatched lymphocytes proliferation by inhibiting naïve, memory and activated T cells, B cell, NK cells and dendritic cells. In addition, adipose tissue-derived MSC (AT-MSC) are becoming an alternative source of MSC for therapeutic applications because adipose tissues are abundant, easily accessible, easily obtainable with little patient discomfort and large amounts of AT-MSC can be easily obtained. A large body of in vitro research has shown that AT-MSC have same or similar immunomodulatory effects with bone marrow derived MSC. Drawing on this finding, the increasing numbers of researchers have turned on their attention to preclinical studies on AT-MSC. As this new path of research evolves with subsequent reports, MSC would make a significant contribution to stem cell therapy or combination therapy for ameliorating symptoms and curing autoimmune disease. By searching and studying the appropriate therapeutic gene, the therapeutic gene transfected stem cell therapy will be able to acquire the synergy effect and the combined advantage of gene therapy and stem cell therapy.

show abstract

Gene therapy using non-viral peptide vector in a canine systemic lupus erythematosus model

Cited by 13 publications

References 26 publications

The effect of gene therapy using CTLA4Ig/silica‐nanoparticles on canine experimental autoimmune thyroiditis

The effect of gene therapy using CTLA4Ig/silica‐nanoparticles on canine experimental autoimmune thyroiditis

New Therapeutic Challenges in Autoimmune Diseases

Adult Stem Cell Therapy for Autoimmune Disease

Contact Info

Product

Resources

About